Overview

Cathflo Activase Pediatric Study

Status:
Completed

Trial end date:
2003-05-01

Target enrollment:

Participant gender:

Summary

This was a Phase IV, open-label, single-arm, multicenter trial that was to be conducted at ~60 sites in the United States. Approximately 300 pediatric subjects with dysfunctional CVADs (including catheters with valves, multiple lumens, umbilical catheters, and implanted ports) were to be treated with up to two serially instilled doses of Cathflo Activase.

Phase:

Phase 4

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Tissue Plasminogen Activator